Anti-obesity medications

Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.

Semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg in people with overweight or obesity but without diabetes, say the STEP 8 investigators.

A randomized trial demonstrates significant reductions in visceral adipose tissue in people with obesity but without diabetes taking the glucagon-like peptide-1 receptor agonist liraglutide.

A randomized trial supports giving people with obesity liraglutide to maintain weight loss after an 8-week diet, particularly if it is combined with regular vigorous exercise.

Click through to read more on this announcement

Findings from a pilot study suggest that the GLP-1 receptor agonist liraglutide might be beneficial for the management of obesity in people with schizophrenia, schizoaffective disorder, or first-episode psychosis.

Click through to read more on this announcement

Liraglutide 3.0 mg boosts weight loss in obese adolescents receiving lifestyle therapy, show the findings of a phase 3 trial.